About Ganymede
Ganymede.bio offers a cloud-based platform that connects scientific data and laboratory instruments to streamline data management for scientists. By automating data handling through its Lab-as-Code technology, the platform saves scientists up to 20% of their time by eliminating manual data entry. Ganymede ensures that all data is FAIR (Findable, Accessible, Interoperable, and Reusable) and provides advanced compliance features for full data flow reproducibility. The company's goal is to modernize laboratory data management systems, allowing scientists to focus more on their research.
Palo Alto, CaliforniaHeadquarters
2022Year Founded
$15.2MTotal Funding
SERIES_ACompany Stage
Data & Analytics, AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees
Benefits
Remote-first role
Periodic reimbursed travel for the team to meet together
Significant equity as an early employee
Unlimited PTO & sick days
Excellent health benefits (medical, dental & vision), life, and disability insurance
Family leave (maternity, paternity, medical, caregiver)
Risks
Increased competition from established biotech software players could challenge Ganymede's market position.
Rapid AI advancements may outpace Ganymede's current offerings, requiring continuous innovation.
Data privacy concerns and regulatory scrutiny could arise with expanded data integration services.
Differentiation
Ganymede offers a low-code bio-aware PaaS for biotech software engineering.
Their Lab-as-Code technology automates data management, saving scientists up to 20% time.
Ganymede ensures data is FAIR, enhancing findability, accessibility, interoperability, and reusability.
Upsides
Partnerships with Elemental Machines and Kytopen expand Ganymede's market reach.
Rising demand for low-code platforms aligns with Ganymede's offerings.
Ganymede's platform supports AI and machine learning, enhancing scientific research capabilities.
Funding
Total raised$15.22 M
Latest valuation$63.75 M
StageSERIES_A
SERIES A
11/30/2022$13
$63.75 MSEED
2/28/2022$3
$14.50 M